Recherche
-
Safety Profile of Medicines Used for the Treatment of Drug-Resistant Tuberculosis: A Descriptive Study Based on the WHO Database (VigiBase((R)))
(Antibiotics. vol. 12, n° 5, 2023-04-25)Article de revueLibre accès -
Impact of Covid-19 Vaccination on Spontaneous Pharmacovigilance Reporting in France
(Drug Safety. vol. 46, n° 12, pp. 1381-1389, 2023-12-01)Article de revue -
First-Line Pharmacotherapies and Survival among Patients Diagnosed with Non-Resectable NSCLC: A Real-Life Setting Study with Gender Prospective
(Cancers. vol. 13, n° 23, 2021-12-05)Article de revueLibre accès -
High prevalence of spin was found in pharmacovigilance studies usingdisproportionality analyses todetectsafetysignals: a meta-epidemiologicalstudy: Spin in pharmacovigilance disproportionality analyses
(Journal of Clinical Epidemiology. vol. 138, pp. 73-79, 2021-06-26)Article de revue -
Will the future of pharmacovigilance be more automated?
(Expert Opinion on Drug Safety. vol. 22, n° 7, pp. 541-548, 2023-07-01)Article de revue -
Antipsychotics and risk of QT prolongation: a pharmacovigilance study
(Psychopharmacology. vol. 240, pp. 199-202, 2022-12-14)Article de revue -
Type I interferons as the potential mechanism linking mRNA COVID-19 vaccines to Bell's palsy
(Thérapie, 2021-04-02)Article de revue -
Pharmacological Evaluation of Signals of Disproportionality Reporting Related to Adverse Reactions to Antiepileptic Cannabidiol in VigiBase
(Pharmaceuticals (Basel). vol. 16, n° 10, pp. 1420, 2023-10-05)Article de revueLibre accès -
Adverse Drug Reaction-Related to Drug Shortage: A Retrospective Study on the French National Pharmacovigilance Database
(British Journal of Clinical Pharmacology. vol. 89, n° 3, pp. 1080-1088, 2023-03)Article de revueLibre accès -
Interpretation of Pharmacovigilance Disproportionality Analyses
(Clinical Pharmacology and Therapeutics, 2023-05-30)Article de revue